RIBER REPORTS IMPROVED RESULTS FOR THE FIRST HALF OF 2026

RIBER reported H1 2026 revenue of €12.7m, up 19% year on year, while gross margin increased 31% to €5.1m and the margin rate expanded 360bps to 39.8%. Net income turned positive at €0.2m versus a €0.8m loss in H1 2025, supported by 71% growth in Services and Accessories revenue. The company secured €6m of financing to industrialize its ROSIE II photonics platform, but its €26.8m order book was constrained by Asia export restrictions that prevented over €8m of orders; 2026 revenue is expected to be broadly flat versus 2025 subject to an export license.

Analysis

ALRIB’s earnings quality is better than the headline growth rate: the mix shift toward aftermarket revenue raises recurring-content, utilization-linked gross profit and should reduce volatility versus lumpy system shipments. That said, the current profitability is too small to support a material rerating without system-order conversion; the decline in systems backlog and the dependence on an export authorization make the near-term revenue bridge fragile. The unaudited interim accounts also warrant a discount until full-year cash conversion is established.

The €6m debt-funded ROSIE II build changes the equity from a net-cash niche tool vendor to a commercialization execution story. If qualification produces repeatable 300mm oxide-on-silicon process performance, ALRIB could gain strategic scarcity value as photonics and quantum customers seek domestic supply chains; however, laboratory interest and wafer pre-orders are not equivalent to production-tool purchase commitments. The more probable 6-18 month outcome is elevated R&D, working-capital and depreciation burden before meaningful platform revenue, pressuring returns if customer qualification slips.

Export-license resolution is the decisive 1-3 month catalyst: approval would validate management’s full-year revenue framework and allow blocked demand to replenish system backlog, while delay turns a nominally flat annual outlook into downside risk concentrated in H2. QUBT and NVO have no investable read-through from this disclosure: any linkage to quantum activity is technological optionality rather than a disclosed customer, supplier, or revenue relationship. Consensus may overvalue the quantum/AI narrative relative to the mundane but investable determinants—license timing, system acceptance milestones, and services attach rate.

The key falsifiers are a failure to secure the license before year-end, systems backlog remaining below €16.5m after the European order is incorporated, or services failing to sustain a high-single-digit-million annualized run rate. Conversely, disclosed ROSIE II customer allocation, paid production-wafer contracts, and H2 operating cash flow sufficient to stabilize net debt would justify increasing exposure.

Key Decisions for Investors

• Maintain ALRIB on watch rather than chase the release; initiate only after export-license approval or a disclosed replacement order that restores systems backlog. Target a 6-12 month position sized for micro-cap liquidity, with a 2:1 minimum upside/downside framework tied to backlog recovery and cash conversion.
• For an existing ALRIB long, reduce exposure if the export license is unresolved by the February 2027 revenue update or if management revises 2026 revenue below the prior-year level; these outcomes would expose operating leverage and debt-funded industrialization risk.
• Add only on evidence that ROSIE II converts from qualification to funded commercial demand: a named production customer, binding tool order, or recurring wafer-contract economics. Treat Q4 sample availability as a technical milestone, not a revenue catalyst.
• Do not use QUBT or NVO as sympathy longs from this development; monitor only for independently confirmed commercial partnerships or procurement disclosures, which are currently missing.